The International Neuromodulation Society

The Fastest-Growing, Worldwide Multidisciplinary Body Devoted to Building Knowledge of Neuromodulation

The International Neuromodulation Society (INS) is a non-profit group of clinicians, scientists and engineers dedicated to the scientific development and awareness of neuromodulation – the alteration of nerve activity through targeted delivery of a stimulus, such as electrical stimulation or chemical agents, to specific neurological sites in the body. The San Francisco-based INS was formed in 1989 and educates and promotes the field through meetings, its peer-reviewed journal Neuromodulation: Technology at the Neural Interface, explanatory content, and chapter websites. The INS also provides information for patients and produces rolling news briefs about this rapidly evolving field.

The INS Peer-Reviewed Journal – 8 Issues a Year

The INS journal Neuromodulation: Technology at the Neural Interface has a growing Impact Factor and is indexed in Index Medicus, MEDLINE and Pubmed from its first issue in 1998. Members may log in to the members-only section to read the journal online.

journal cover

+Submit a Manuscript.+

What is Neuromodulation?

Medical Professionals can learn about various considerations concerning neuromodulation and clinic contacts. Once your preliminary questions have been answered, please use the Contact Us facility to find out more and to discuss specific objectives. Others may simply wish to join the INS and one of its related chapter societies, please use the Membership Application.

Clinical trials that involve a wide range of emerging neuromodulation approaches are listed on our Research page. Neuromodulation clinical trials address symptom control through nerve stimulation in such condition categories as:

If you are not a medical professional and you are searching for information about neuromodulation and how these types of treatment could benefit a specific condition such as treatment-resistant headache or other chronic pain syndromes, you may find the sections titled Therapies, About Neuromodulation or FAQs particularly helpful.

Members may log in and visit the members-only section’s Global Discussion Forum

Breaking News Share

International Neuromodulation Society Innovations Day Will Focus on Disruptive Advances

April 22, 2019 - The International Neuromodulation Society announced its 5th Innovations Day, a preconference of the INS World Congress devoted to presentations and keynote talks about the development of neuromodulation technology, from early stage ventures to advanced stage companies and markets. (Seeking Alpha)

FDA Approves a Noninvasive Neurostimulation Device for Attention-Deficit Hyperactivity Disorder

April 20, 2019 - The U.S. FDA has approved a external trigeminal nerve stimulation system to treat ADHD i children aged 7 - 12 who are not taking medication for the disorder. (USA Today)

Analysis Suggests Plasticity May Play a Role in Effect of Responsive Neurostimulation in Epilepsy

April 19, 2019 - An analysis of seizure patterns in patients implanted with a responsive neurostimulation system for epilepsy suggests the therapy exerts its effects by remodulating neural networks. (Medscape)

Company Starts Clinical Trial of a Wearable Device for Overactive Bladder in Women

April 19, 2019 - FemPulse has launched a clinical trial to enroll 21 women at three U.S. cites in a trial of the company's intravaginal neuromodulation device intended to address overactive bladder. (MD+DI)

Paper Presents Two Decades of Device and Therapy Survival Data

April 2019 - Researchers analyzed device and therapy survival data at one institution from 1994 - 2015 for three neuromodulation therapies: deep brain stimulation, vagus nerve stimulation, and spinal cord stimulation. (Journal of Neurosurgery)

To see select neuromodulation news by category, as well as news about the INS in particular, please visit the Newsroom. To see archived news briefs dating back to January 2011, visit the News Archive.

Continue Reading News Briefs
Last Updated on Monday, December 12, 2016 10:01 AM